

Member FINRA/SIPC

Toll-Free: 866-928-0928 ♦ www.DawsonJames.com ♦ 101 North Federal Highway - Suite 600 ♦ Boca Raton, FL 33432

HeartBeam (NASDAQ: BEAT) - Buy

August 21, 2023

HeartBeam – Second Quarter Results

Jason Kolbert
Managing Director & Senior Analyst
jkolbert@dawsonjames.com

HeartBeam announced second quarter results. The company spent \$3.3M in the quarter and raised \$24.3M. The company also submitted a 510(k) for the AIMIGO system.


Investment Highlights

Second Quarter Highlights:

- Closed a secondary offering and registered direct offering for gross proceeds of \$26.5 million to enable company to execute on upcoming clinical and regulatory milestones and extend cash runway into late 2024.
- Submitted a 510(k) application to the U.S. Food and Drug Administration (FDA) for the HeartBeam AIMIGo System; Withdrew the 510(k) application for HeartBeam AIMI to focus on HeartBeam AIMIGo
- Announced the publication, in JACC: Advances, of a foundational study demonstrating the ability of HeartBeam’s VECG technology platform to detect the presence of coronary artery occlusions.
- Strengthened Board of Directors with the appointment of several respected industry executives, including Dr. Michael Jaff, Ken Nelson and Mark Strome, bringing the number of HeartBeam board members to eight.
- Appointed experienced cardiology regulatory specialist, Deborah Castillo, PhD, as Vice President of Regulatory.
- Announced that US PTO granted an automated cardiac detection patent for the HeartBeam AIMIGo System, underscoring the Company’s IP leadership position in VECG.

Valuation: We have adjusted our model for the recent raise. We project our model out to 2030. We apply a 30% risk cut to our projected revenues in our product model in addition to our 30% risk rate applied in our Free Cash Flow to the Firm (FCFF), discounted EPS (dEPS), and Sum-of-the-Parts (SOP) models. The result is equal-weighted and averaged and rounded to the nearest whole number to derive our 12-month projected price target of \$6.0.

Risks to our thesis include: 1. Regulatory Approvals; 2. Clinical Science 3. Adoption Rates 4. The competitive landscape. 5. Intellectual Capital 6. Dilution.



- **Regulatory Approvals.** The company's products require regulatory approvals, and there can be no assurances that the requirements to achieve these approvals can be met.
- **Clinical Science:** The company will need to demonstrate to its "sophisticated" clients (cardiologists) that the product works and is comparable to the existing standard of care.
- **Adoption Rates:** There are no assurances that our projected market share can be met. A combination of factors from pricing and reimbursement to competitive performance are expected to be key factors in driving users to select the product for their practices, patients, and the emergency room setting.
- **The Competitive Landscape & IP.** The company does have intellectual property and knows how to protect the utility of its devices and software; however, we expect that the technology cycle is competitive, and the company may face competition from well-financed competitors who are already in position in the target markets.
- **Dilution:** The company is likely to incur losses for the foreseeable future until it is able to generate sufficient revenue from product sales. Our model assumes a rising share count. There can be no assurances that the company can successfully raise the capital required to execute its business strategy.


Exhibit 1. Income Statement

Heart Beam: Income Statement (\$000)													
∴ YE December 31	2022A	1Q23A	2Q23A	3Q23E	4Q23E	2023E	2024E	2025E	2026E	2027E	2028E	2029E	2030E
Product sales													
ED Software		-	-	-	-	-	1,780	18,103	36,823	37,452	38,091	46,489	47,283
ECG Monitor		-	-	-	-	-	14,921	31,266	52,067	74,167	100,975	207,452	326,016
Total Product Sales		-	-	-	-	-	16,701	49,368	88,891	111,618	139,066	253,941	373,299
Expenses													
COGS							3,340	9,874	14,222	15,627	16,688	25,394	37,330
COGS %							20%	20%	16%	14%	12%	10%	10%
General & Administrative	7,354	2,475	1,828	2,008	2,085	7,722	12,000	18,000	30,000	30,600	31,212	31,836	32,473
Research and Development	5,677	1,681	1,484	936	972	3,600	3,672	7,000	10,000	12,000	15,000	15,300	15,606
Total expenses	13,031	4,156	3,312	2,944	3,057	11,322	19,012	34,874	54,222	58,227	62,900	72,530	85,409
Operating Income (Loss)	(13,031)	(4,156)	(3,312)	(2,944)	(3,057)	(11,322)	(2,311)	14,495	34,668	53,392	76,166	181,411	287,890
Finance income													
Finance expenses	69	20	158										
Total other income	69	20	158	-	-	-	-	-	-	-	-	-	-
Pretax Income	(12,962)	(4,136)	(3,154)	(2,944)	(3,057)	(11,322)	(2,311)	14,495	34,668	53,392	76,166	181,411	287,890
change in fair value of cash flow hedge													
Income Tax Benefit (Provision)	-	-	-	-	-	-	-	1,449	5,200	13,348	22,850	63,494	109,398
Tax Rate	0%	0%	0%	0%	0%	0%	0%	10%	15%	25%	30%	35%	38%
GAAP Net Income (loss)	(12,962)	(4,136)	(3,154)	(2,944)	(3,057)	(11,322)	(2,311)	13,045	29,468	40,044	53,316	117,917	178,492
GAAP-EPS	(2.72)	(0.50)	(0.16)	(0.12)	(0.12)	(0.90)	(0.09)	0.52	1.17	1.58	2.09	4.61	6.95
GAAP EPS (dil)	(1.59)	(0.50)	(0.13)	(0.08)	(0.09)	(0.44)	(0.06)	0.35	0.75	0.98	1.25	2.67	3.88
Wgtd Avg Shrs (Bas) - '000s	8,169	8,222	19,690	25,000	25,025	19,484	25,088	25,188	25,289	25,390	25,492	25,594	25,697
Wgtd Avg Shrs (Dil) - '000s	8,169	8,222	24,971	35,000	35,350	25,886	36,243	37,714	39,246	40,839	42,497	44,223	46,019

Source: Dawson James

Companies mentioned in this report:

Important Disclosures:



Price target and ratings changes over the past three years:

- Initiated – Buy – July 25, 2022 – Price Target \$12.00
- Update Report – Buy – August 12, 2022 – Price Target \$12.00
- Update Report – Buy – September 20, 2022 – Price Target \$12.00
- Update Report – Buy – September 30, 2022 – Price Target \$12.00
- Update Report – Buy – October 5, 2022 – Price Target \$12.00
- Update Report – Buy – November 11, 2022 – Price Target \$12.00
- Update Report – Buy – November 17, 2022 – Price Target \$12.00
- Update Report – Buy – December 7, 2022 – Price Target \$12.00
- Update Report – Buy – March 8, 2023 – Price Target \$12.00
- Update Report – Buy – March 15, 2023 – Price Target \$12.00
- Update Report – Buy – March 17, 2023 – Price Target \$12.00
- Price Target Change – Buy – May 22, 2023 - Price Target goes from \$12.0 to \$6.0
- Update Report - Buy - August 21, 2023 - Price Target \$6.0

Dawson James Securities, Inc. (the "Firm") is a member of the Financial Industry Regulatory Authority ("FINRA") and the Securities Investor Protection Corporation ("SIPC").

The Firm does not make a market in the securities of the subject company(s). The Firm has not engaged in investment banking relationships with the subject company in the prior twelve months, as a manager or co-manager of a public offering and has not received compensation resulting from those relationships. The Firm may seek compensation for investment banking services in the future from the subject company(s). The Firm has received other compensation from the subject company(s) in the last 12 months for services unrelated to managing or co-managing of a public offering.

Neither the research analyst(s) whose name appears on this report nor any member of his (their) household is an officer, director, or advisory board member of these companies. The Firm and/or its directors and employees may own securities of the company(s) in this report and may increase or decrease holdings in the future. As of August 17, 2023, the Firm as a whole did not beneficially own 1% or more of any class of common equity securities of the subject company(s) of this report. The Firm, its officers, directors, analysts, or employees may affect transactions in and have long or short positions in the securities (or options or warrants related to those securities) of the company(s) subject to this report. The Firm may affect transactions as principal or agent in those securities.

Analysts receive no direct compensation in connection with the Firm's investment banking business. All Firm employees, including the analyst(s) responsible for preparing this report, may be eligible to receive non-product or service-specific monetary bonus compensation that is based upon various factors, including total revenues of the Firm and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.

Although the statements in this report have been obtained from and are based upon recognized statistical services, issuer reports or communications, or other sources that the Firm believes to be reliable, we cannot guarantee their accuracy. All opinions and estimates included in this report constitute the analyst's judgment as of the date of this report and are subject to change without notice.

Information about valuation methods and risks can be found in the "Valuation" and "Risk Analysis" sections of this report.

The securities of the company discussed in this report may be unsuitable for investors depending on their specific investment objectives and financial position. This report is offered for informational purposes only and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such would be prohibited. Additional information is available upon request.

Ratings Definitions:

- 1) **Buy:** The analyst believes the price of the stock will appreciate and produce a total return of at least 20% over the next 12-18 months.
- 2) **Neutral:** The analyst believes the price of the stock is fairly valued for the next 12-18 months.
- 3) **Sell:** The analyst believes the price of the stock will decline by at least 20% over the next 12-18 months and should be sold.

The following chart reflects the range of current research report ratings for all companies, followed by the analysts of the Firm. The chart also reflects the research report ratings relating to those companies for which the Firm has performed investment banking services.

Current as of 3-Aug-23

	Company Coverage		Investment Banking	
Ratings Distribution	# of Companies	% of Total	# of Companies	% of Totals
Market Outperform (Buy)	24	69%	3	8.60%
Market Perform (Neutral)	11	31%	3	8.60%
Market Underperform (Sell)	0	0%	0	0.00%
Total	35	100%	6	17.20%

Analyst Certification:

The analyst(s) whose name appears on this research report certifies that 1) all of the views expressed in this report accurately reflect his (their) personal views about any and all of the subject securities or issuers discussed; and 2) no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst in this research report; and 3) all Dawson James employees, including the analyst(s) responsible for preparing this research report, may be eligible to receive non-product or service-specific monetary bonus compensation that is based upon various factors, including total revenues of Dawson James and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.